TGFB1 and cancer: Combination therapy using a TGF-βR inhibitor to target CAFs has shown promise in enhancing the efficacy of immunotherapy.69 Moreover, Dominguez et al. identified a population of CAFs programmed by TGF-β that express leucine-rich repeat containing 15 proteins, which is valuable for detecting poor responses to ICI treatment in multiple cancer types.